Breaking News
AbbVie
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
For more information about AbbVie, please visit us at www.abbvie.com.
FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
April 18 2023
AbbVie today announced that the United States Food and Drug Administration (FDA) has approved expanding […]
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
April 17 2023
AbbVie has announced the European Commission (EC) approved RINVOQ (upadacitinib, 45 mg [induction dose] and 15 […]
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
February 23 2023
AbbVie and Capsida Biotherapeutics today announced an expanded strategic collaboration to develop genetic medicines for […]
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators
January 10 2023
AbbVie and Anima Biotech (Anima) today announced a collaboration to discover and develop mRNA biology modulators […]
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
January 6 2023
AbbVie and Immunome, a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform […]
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
December 6 2022
AbbVie and HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of small molecule […]
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
November 23 2022
AbbVie announced the European Commission (EC) has approved SKYRIZI (risankizumab, 600 mg intravenous [IV] induction and […]
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
July 22 2022
AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop […]
RINVOQ ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
March 17 2022
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved […]
AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
March 11 2022
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. (‘Richter’) today announced a new co-development and license […]
AbbVie and REGENXBIO Announce Eye Care Collaboration
September 14 2021
AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and […]
AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
July 27 2021
AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration […]
AbbVie’s RINVOQ® ▼ (upadacitinib) Accepted for Use
May 11 2021
AbbVie (NYSE: ABBV) today announced that the Scottish Medicines Consortium (SMC) has issued a positive […]